Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment.
ImmunityBio, Inc. , a commercial-stage immunotherapy company developing cytokine and cellular immunotherapies designed to ...
The partners will use 4D Path's imaging-based Q-Plasia OncoReader in a Phase II trial testing doublet and triplet regimens comprising Trodelvy, Padcev, and Keytruda.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback